Specialty pharmaceutical company Aspargo Labs, Inc. has appointed a University of the West of Scotland (UWS) graduate to its international leadership team.

Alumnus Dr Pallav Shah will join as Director of Regulatory Affairs, Europe, for the pharmaceutical and MedTech company, which is focused on converting the world’s most meaningful medications into liquid oral suspensions for delivery in proprietary digitally connected devices.

“The addition of Dr Shah is a deliberate expansion of our global capabilities at a critical inflection point,” said Michael Demurjian, Chief Executive Officer & Chairman of Aspargo Labs. “Dr Shah’s proven regulatory expertise with complex regulatory submissions directly align with our immediate priorities: accelerating significant sales growth and commercializing oral liquid suspensions in major international markets.”

Dr Shah studied at UWS Paisley Campus and was awarded a PhD in 2013 from UWS, where his research focused on the synthesis and evaluation of novel compounds for the treatment of hormone-dependent breast cancer.

Previously, Dr Shah served as Chief Executive Officer of Cambridge Regulatory Services, where he oversaw regulatory strategy, pharmacovigilance operations, and medical information services.

His experience includes managing marketing authorization applications, clinical trial applications, risk-benefit assessments, and ensuring adherence to international regulatory standards. At Cambridge Regulatory services, Dr Shah successfully obtained marketing authorizations for over 30 products in multiple countries.